Back to Search
Start Over
Testing algorithm for identification of patients with TRK fusion cancer.
- Source :
-
Journal of clinical pathology [J Clin Pathol] 2019 Jul; Vol. 72 (7), pp. 460-467. Date of Electronic Publication: 2019 May 09. - Publication Year :
- 2019
-
Abstract
- The neurotrophic tyrosine receptor kinase ( NTRK ) gene family encodes three tropomyosin receptor kinases (TRKA, TRKB, TRKC) that contribute to central and peripheral nervous system development and function. NTRK gene fusions are oncogenic drivers of various adult and paediatric tumours. Several methods have been used to detect NTRK gene fusions including immunohistochemistry, fluorescence in situ hybridisation, reverse transcriptase polymerase chain reaction, and DNA- or RNA-based next-generation sequencing. For patients with TRK fusion cancer, TRK inhibition is an important therapeutic target. Following the FDA approval of the selective TRK inhibitor, larotrectinib, as well as the ongoing development of multi-kinase inhibitors with activity in TRK fusion cancer, testing for NTRK gene fusions should become part of the standard diagnostic process. In this review we discuss the biology of NTRK gene fusions, and we present a testing algorithm to aid detection of these gene fusions in clinical practice and guide treatment decisions.<br />Competing Interests: Competing interests: FP-L has participated in advisory boards for Bayer, Roche, Illumina and Nanostring, and been involved in studies sponsored by Bayer. ERR has had a role as an expert consultant, participated in a meeting and participated in an advisory board for Bayer Healthcare Pharmaceuticals. ARS has had a role as an expert consultant for Merck US, Bristol Meyers Squibb and Bayer Healthcare Pharmaceuticals; participated in meetings for Merck US, Bristol Meyers Squibb and Bayer Healthcare Pharmaceuticals; participated in advisory boards for Merck US, Bristol Meyers Squibb and Bayer Healthcare Pharmaceuticals; and received honoraria from Amgen.<br /> (© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Subjects :
- Algorithms
Humans
Membrane Glycoproteins antagonists & inhibitors
Membrane Glycoproteins genetics
Neoplasms drug therapy
Neoplasms enzymology
Nerve Growth Factors antagonists & inhibitors
Receptor Protein-Tyrosine Kinases antagonists & inhibitors
Receptor, trkA antagonists & inhibitors
Receptor, trkA genetics
Receptor, trkB antagonists & inhibitors
Receptor, trkB genetics
Receptor, trkC antagonists & inhibitors
Receptor, trkC genetics
Neoplasms genetics
Nerve Growth Factors genetics
Oncogene Proteins, Fusion genetics
Protein Kinase Inhibitors therapeutic use
Pyrazoles therapeutic use
Pyrimidines therapeutic use
Receptor Protein-Tyrosine Kinases genetics
Subjects
Details
- Language :
- English
- ISSN :
- 1472-4146
- Volume :
- 72
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Journal of clinical pathology
- Publication Type :
- Academic Journal
- Accession number :
- 31072837
- Full Text :
- https://doi.org/10.1136/jclinpath-2018-205679